<SEC-DOCUMENT>0001520138-21-000754-index.html : 20211201
<SEC-HEADER>0001520138-21-000754.hdr.sgml : 20211201
<ACCEPTANCE-DATETIME>20211201091548
ACCESSION NUMBER:		0001520138-21-000754
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		16
CONFORMED PERIOD OF REPORT:	20211130
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
ITEM INFORMATION:		Unregistered Sales of Equity Securities
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20211201
DATE AS OF CHANGE:		20211201

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIOVIE INC.
		CENTRAL INDEX KEY:			0001580149
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				462510769
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39015
		FILM NUMBER:		211461585

	BUSINESS ADDRESS:	
		STREET 1:		2120 COLORADO AVE.
		STREET 2:		SUITE 230
		CITY:			LOS ANGELES
		STATE:			CA
		ZIP:			90404
		BUSINESS PHONE:		310-444-4300

	MAIL ADDRESS:	
		STREET 1:		2120 COLORADO AVE.
		STREET 2:		SUITE 230
		CITY:			LOS ANGELES
		STATE:			CA
		ZIP:			90404

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NANOANTIBIOTICS, INC.
		DATE OF NAME CHANGE:	20130625
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>bivi-20211130_8k.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
Document 1 - file: bivi-20211130_8k.htm

</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>bivi-20211130_8kex10z1.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
Document 2 - file: bivi-20211130_8kex10z1.htm

</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>bivi-20211130_8kex10z2.htm
<DESCRIPTION>EXHIBIT 10.2
<TEXT>
Document 3 - file: bivi-20211130_8kex10z2.htm

</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>4
<FILENAME>bivi-20211130_8kex10z3.htm
<DESCRIPTION>EXHIBIT 10.3
<TEXT>
Document 4 - file: bivi-20211130_8kex10z3.htm

</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>5
<FILENAME>bivi-20211130_8kex99z1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
Document 5 - file: bivi-20211130_8kex99z1.htm

</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>bivi-20211130_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
Document 6 - file: bivi-20211130_pre.xml

</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>bivi-20211130.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
Document 7 - file: bivi-20211130.xsd

</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>bivi-20211130_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
Document 8 - file: bivi-20211130_lab.xml

</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>bivi-20211130_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
Document 9 - file: bivi-20211130_8k_htm.html

Document 9 - RAW XML: bivi-20211130_8k_htm.xml

</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
Document 10 - file: R1.htm

</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>11
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
Document 11 - file: Financial_Report.xlsx

</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
Document 12 - file: Show.js

</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
Document 13 - file: report.css

</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
Document 14 - file: FilingSummary.html

Document 14 - RAW XML: FilingSummary.xml

</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>16
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
Document 16 - file: MetaLinks.json

</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>17
<FILENAME>0001520138-21-000754-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
Document 17 - file: 0001520138-21-000754-xbrl.zip

</DOCUMENT>
</SEC-DOCUMENT>